Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;11(3):289-295.
doi: 10.1111/cts.12534. Epub 2018 Jan 8.

Developing Pharmacogenomic Reports: Insights from Patients and Clinicians

Laney K Jones  1 , Alanna Kulchak Rahm  1 , Michael R Gionfriddo  1 , Janet L Williams  1 , Audrey L Fan  1   2 , Rebecca A Pulk  1 , Eric A Wright  1 , Marc S Williams  1
Affiliations

Developing Pharmacogenomic Reports: Insights from Patients and Clinicians

Laney K Jones et al. Clin Transl Sci. 2018 May.

Abstract

Increasingly, for a variety of indications, patients have their genomes sequenced and actionable results returned. A subset of returned results is pharmacogenomic (PGx) variants involved in the metabolism or action of medications. Although the impact of these variants on health is well-documented, little research exists on how to communicate these findings to patients and clinicians. We conducted semistructured interviews with end users to understand how best to communicate PGx results. Overall, patients and clinicians had similar opinions regarding report content, delivery, and application. Unique concerns specific to each stakeholder group were also expressed. Patients wanted an easy-to-understand individualized report that clinicians utilized to guide their care. Clinicians wanted reports that were easy-to-use, actionable, and integrated into their workflow. Implementation of these reports in a clinical setting will allow for broader user feedback and iterative improvement.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Report sections of mock concept sheets to patient and clinician by gene and presentation of report.
Figure 2
Figure 2
Description of iterative process.
See this image and copyright information in PMC

References

    1. Moaddeb, J. & Haga, S.B. Pharmacogenetic testing: current evidence of clinical utility. Ther. Adv. Drug Saf. 4, 155–169 (2013). - PMC - PubMed
    1. Patel, H.N. , Ursan, I.D. , Zueger, P.M. , Cavallari, L.H. & Pickard, A.S. Stakeholder views on pharmacogenomic testing. Pharmacotherapy 34, 151–165 (2014). - PubMed
    1. Johnson, J.A. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics 14, 835–843 (2013). - PMC - PubMed
    1. Haga, S.B. & Burke, W. Pharmacogenetic testing: not as simple as it seems. Genet. Med. 10, 391–395 (2008). - PubMed
    1. Mills, R. , Voora, D. , Peyser, B. & Haga, S.B. Delivering pharmacogenetic testing in a primary care setting. Pharmgenomics Pers. Med. 6, 105–112 (2013). - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources